-
Blowout Microsoft results lift US stocks as oil retreats
-
Grynspan ahead in process to pick next UN chief: diplomats
-
De Minaur beats teen Hewitt in Washington all-Aussie clash
-
Thitikul leads from history-chasing Ryu at women's British Open
-
England's Stones joins Inter Milan on free transfer
-
Hundreds of migrants flood into Spain's Ceuta exclave from Morocco
-
Renewed Iran war raises US missile supply concerns
-
French minister defends expulsion order against Russian commentator
-
Nobel Peace Prize winner Murad says justice for Yazidis far too slow
-
Milei demands expulsion of foreigners expressing 'hate' against Argentina
-
Mexico escalates war against smelly seaweed on Caribbean beaches
-
UK's highest court to hear Palestine Action's appeal against ban
-
Selection process for next UN chief under way
-
Hundreds of migrants swim to Spain's Ceuta territory from Morocco
-
UEFA says will boycott World Cup if FIFA pushes private investor proposal
-
'Beginning of the end': Relief but no party as French wildfire winds down
-
Volunteers rush to feed scared animals in fire-stricken France
-
UEFA says will boycott World Cup over FIFA proposals
-
Russian missile strike destroys family home, 10 feared dead
-
Rashford says final goodbye to Barcelona ahead of Man Utd return
-
Djokovic to make return at Cincinnati Masters
-
History-chasing Ryu sets pace at women's British Open
-
Selection process for next UN chief begins
-
Italy's Po River valley on drought alert
-
Southern Europe 'becoming more flammable' in hotter climate, experts say
-
France, Spain eye wildfire reprieve as other blazes start up in Europe
-
Prada profits pinched as growth hard to chase
-
Mammoth bones found on parched bed of Danube in Bulgaria
-
Turkey confronts growing wildfires on tourist coasts
-
Atletico complain to FIFA over Barca's Alvarez approach
-
Stocks climb on earnings and rates, oil retreats
-
MEXC Lists Grvt (GRVT) with $60,000 Worth of GRVT and 10,000 USDT in Airdrop+ Rewards
-
Russia blamed for missile that blasted crater in Polish field
-
Musk plans major Republican midterm spending push: report
-
US economic growth slows in second quarter, missing expectations
-
George and Amal Clooney flee French home due to wildfire
-
Russia adds Telegram founder Durov to 'terrorist' blacklist
-
Howe set to leave Newcastle, with Al-Ahli's Jaissle to take over: reports
-
MEXC Ventures Supports Alpha Arena's APAC Debut at Coinfest Bali
-
Ugandan opposition leader in intensive care: wife
-
Grealish hits back over Man City tour snub claims
-
France firefighters hopeful, as Spain ends national emergency
-
Firefighters battle to contain deadly Crete blaze in Greece
-
Stocks diverge on earnings, as oil steadies
-
Chelsea sign France defender Lacroix from Crystal Palace
-
AI data centre supplier Zhongji InnoLight slips on Hong Kong debut
-
Root named England Test captain, Fleming appointed coach
-
Eurozone economy grows despite Middle East war
-
May, June heatwaves caused 2,877 extra deaths in England: govt
-
Singapore group will develop 'most promising' Ebola vaccine
Canada health authority approves Pfizer's anti-Covid pill
Canada's health authority said Monday it has approved Pfizer's anti-Covid pill, Paxlovid, for adults at high risk of progressing to serious disease.
The oral treatment was approved after an "expedited review," Health Canada said in a statement on its website, adding that it would continue to monitor its safety and effectiveness.
"No drug, including PAXLOVID TM, is a substitute for vaccination," the statement added.
The drug, which comprises two types of tablet, is the first Covid-19 therapy which can be taken at home, and is potentially a huge step towards ending the pandemic.
"Today's announcement is particularly important as access to easy-to-use treatments could help to reduce the severity of Covid-19 in adults who become newly infected and are at high-risk of progressing to serious illness," said Theresa Tam, Canada's chief public health officer.
The approval comes as Canada, like many countries, has been struggling to contain the Omicron variant of Covid-19.
The French-speaking province of Quebec recently announced it would levy a tax on the unvaccinated, arguing they impose a burden on everyone else.
Paxlovid has so far been authorized in a handful of countries including the United States and Israel, while the European Union has allowed member states to use it ahead of formal approval as an emergency measure against Omicron.
Unlike vaccines, it does not target the ever-evolving spike protein which the coronavirus uses to invade cells.
It should therefore in theory be more variant-proof, and the company has said preliminary lab studies have backed up that hypothesis.
A.O.Scott--AT